The global embolization coils market is estimated to surpass an amazing valuation of US$ 1,200 Million in 2022, with a compound annual growth rate (CAGR) of 5% projected from 2022 to 2032, reaching a market value of US$ 1,954.56 Million. Factors such as rising vascular disease prevalence, technological developments in embolization products and techniques, increased R&D efforts, and rising demand for minimally invasive procedures are propelling market expansion.
Cerebrovascular disease, coronary heart disease, rheumatic heart disease, and other illnesses are examples of cardiovascular diseases (CVDs). Tobacco use, a poor diet, and physical inactivity all raise the risk of heart attack and stroke. CVDs are the largest cause of death worldwide, affecting more individuals than any other disease.
The occurrence of cardiac aneurysms is increasing worldwide. According to the Society for Vascular Surgery (SVS), 2 million persons in the United States are diagnosed with an abdominal aortic aneurysm each year. A ruptured abdominal aortic aneurysm is also listed as the 15th top cause of mortality in the country. It is most typically seen in those over the age of 55. As a result, the increasing occurrence of cardiac aneurysms is driving the growth of the embolization coils market.
In July 2021, Terumo Medical Corporation (TMC) introduced its AZUR Vascular Plug, the first and only plug compatible with a microcatheter to occlude arteries up to 8mm in diameter. The newest addition to Terumo’s robust embolization portfolio is indicated for use to reduce or block the rate of blood flow in arteries of the peripheral vasculature.
In April 2021, the US Food and Drug Administration (FDA) approved the Pipeline Flex Embolization Device with Shield Technology of Medtronic PLC, which was indicated primarily for brain aneurysms. Shield Technology enhances the flow diverter device by decreasing thrombogenicity caused due to the material.
In August 2022, MicroPort Scientific Corporation announced that it has received approval from the Colombian Institute for Drug and Food Surveillance (INVIMA) for its MinosTM Abdominal Aortic Stent-Graft and Delivery System. As a brand new abdominal aortic stent-graft system independently developed by Endovastec™, the Minos™ System is designed for the interventional therapy of infrarenal aortic aneurysms. It is the first domestically made stent-graft system which features an ultra-low profile delivery system with an outer diameter of 14F.
Boston Scientific Corporation offers the Pushable 0.018” and 0.035” Embolization Coils. These coils offer successful embolization through a systematic approach including guidewires, catheters, coils, and/or embolic materials. The VortX 18 and 35 Vascular Occlusion Coils are designed with a proprietary conical shape and an apex-first deployment. VortX Coils are pushable coils designed to provide compact, complete vascular occlusion and efficient embolization.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E Mail : sales@factmr.com
This Press Release has been written with the intention of providing accurate market information which will enable our readers to make informed strategic investment decisions. If you notice any problem with this content, please feel free to reach us on mediarelations@xherald.com.
Xherald
Xherald is passionate about offering extensive coverage of global business news. Dedicated to creating every participant's notification, it reaches its own reader. Daily our experts offer fresh relevant information regarding what is actually occurring in Markets as well as Business. Our headlines are actually swiftly paced and extensive. Our distributor directory connects you with brand new products or services and its market situation from the most effective companies around the planet. Xherald is driven by its 500+ contributors coming from around the world. Xherald provides local as well as global market intelligence information coverage in sectors ranging from healthcare, IOT, chemicals and 17 more sectors. Our updates are quickly paced and detailed. The news we present is actually a mix of authentic content, community contributions and curated headlines announcements. All of the updates our company supplies must pass a strict criterion of genuineness, relevance and significance to our readers.